Soleno Therapeutics Inc
SLNODelisted May 18, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001484565
Soleno Therapeutics Inc was delisted on May 18, 2026; its insiders filed their last Form 4 on May 18, 2026; 227 institutions reported holding it in 13F filings for Q1 2026, worth $2.09B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Soleno Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Soleno Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hahn Mark W | Director | 0 | May 18, 2026 | 2 |
| Pauls Matthew | Director | 0 | May 18, 2026 | 1 |
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | 0 | May 18, 2026 | 3 |
| Yen Kristen | SEE REMARKS | 0 | May 18, 2026 | 3 |
| Bir Dawn Carter | Director | 0 | May 18, 2026 | 1 |
| Manning Meredith | Chief Commercial Officer | 0 | May 18, 2026 | 4 |
| Volck Birgitte | Director | 0 | May 18, 2026 | 1 |
| Sinclair Andrew | Director | 0 | May 18, 2026 | 1 |
| Hirano Patricia C | SEE REMARKS | 0 | May 18, 2026 | 3 |
| Norrett Kevin | Chief Business Officer | 0 | May 18, 2026 | 3 |
| Fulk Jennifer | CHIEF FINANCIAL OFFICER | 0 | May 18, 2026 | 2 |
| Joshi Manher | Chief Development Officer | 0 | May 18, 2026 | 3 |
| Huang Michael F. | Sr. VP of Clinical Development | 0 | May 18, 2026 | 4 |
| Mackaness James H | CHIEF FINANCIAL OFFICER | 131,763 | Jan 23, 2026 | 2 |
| Harris William G | Director | 19,392 | Jun 9, 2025 | 0 |
| Vivo Opportunity, LLC | 10% Owner | 4,458,294Indirect | Mar 28, 2025 | 0 |
| Vivo Opportunity Fund Holdings, L.P. | 10% Owner | 4,458,294Indirect | Mar 28, 2025 | 0 |
| Urbanski Raymond W. | CHIEF DEVELOPMENT OFFICER | – | Aug 23, 2024 | 0 |
| Mario Ernest | Director | 193,066 | Jun 10, 2024 | 0 |
| TC Group, LLC | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Carlyle Investment Management LLC | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Abingworth LLP | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Carlyle Group Inc. | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Carlyle Holdings I GP Inc. | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Carlyle Holdings I GP Sub L.L.C. | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Carlyle Holdings I L.P. | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Abingworth Bioventures VII LP | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| CG Subsidiary Holdings L.L.C. | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Carlyle Genesis UK LLC | 10% Owner | 1,531,436Indirect | Oct 2, 2023 | 0 |
| Edelman Joseph | 10% Owner | 3,074,542Indirect | Sep 28, 2023 | 0 |
| Perceptive Advisors LLC | 10% Owner | 3,074,542Indirect | Sep 28, 2023 | 0 |
| Perceptive Life Sciences Master Fund Ltd | 10% Owner | 3,074,542Indirect | Sep 28, 2023 | 0 |
| Melincoff Gwen A | Director | – | May 26, 2023 | 0 |
| Schuler Jack W | 10% Owner | 36,595Indirect | May 15, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2024 (view filing)1:10 PM ET | Apr 29-30 | 2 days | Vivo Opportunity, LLC and 1 other10% Owner | SSale | −1.10M | $46.95 | −$51.7M | −13.1%7.32M after | 2 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Anish BhatnagarCHIEF EXECUTIVE OFFICER | SSale | −19.3K | $41.54 | −$799.9K | −12.6%133.5K after | 2 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −2.17K | $41.54 | −$90.1K | −4.3%48.8K after | 2 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −7.19K | $41.54 | −$298.7K | −11.4%55.8K after | 2 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Yen KristenSEE REMARKS | SSale | −2.17K | $41.54 | −$90.1K | −9.3%21.3K after | 2 lots |
| Aug 7, 2024 (view filing) | Aug 5-6 | 2 days | Anish BhatnagarCHIEF EXECUTIVE OFFICER | SSale | −127.3K | $45.60 | −$5.81M | −12.9%856.2K after | 5 lots |
| Aug 7, 2024 (view filing) | Aug 5-6 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −11.0K | $45.60 | −$502.0K | −8.2%122.7K after | 5 lots |
| Aug 7, 2024 (view filing) | Aug 5-6 | 2 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −15.0K | $45.60 | −$683.2K | −9.6%140.8K after | 5 lots |
| Aug 7, 2024 (view filing) | Aug 5-6 | 2 days | Yen KristenSEE REMARKS | SSale | −11.0K | $45.60 | −$500.4K | −10.3%95.3K after | 5 lots |
| Aug 29, 2024 (view filing)7:36 PM ET | Aug 27-29 | 2 days | Vivo Opportunity, LLC and 1 other10% Owner | SSale | −1.02M | $48.01 | −$49.2M | −14.0%6.29M after | 3 lots |
| Aug 30, 2024 (view filing) | Aug 28-29 | 2 days | Anish BhatnagarCHIEF EXECUTIVE OFFICER | SSale | −115.0K | $47.43 | −$5.45M | −13.4%741.2K after | 4 lots |
| Aug 30, 2024 (view filing) | Aug 28-29 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −10.7K | $47.43 | −$507.7K | −8.7%112.0K after | 4 lots |
| Aug 30, 2024 (view filing) | Aug 28-29 | 2 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −13.5K | $47.43 | −$641.8K | −9.6%127.2K after | 4 lots |
| Aug 30, 2024 (view filing) | Aug 28-29 | 2 days | Yen KristenSEE REMARKS | SSale | −10.7K | $47.43 | −$507.7K | −11.2%84.6K after | 4 lots |
| Oct 3, 2024 (view filing) | Oct 1 | 2 days | Anish BhatnagarCHIEF EXECUTIVE OFFICER | SSale | −21.6K | $49.43 | −$1.07M | −2.9%719.6K after | 2 lots |
| Oct 3, 2024 (view filing) | Oct 1 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −3.11K | $49.43 | −$153.6K | −2.8%108.9K after | 2 lots |
| Oct 3, 2024 (view filing) | Oct 1 | 2 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −8.08K | $49.43 | −$399.3K | −6.3%119.2K after | 2 lots |
| Oct 3, 2024 (view filing) | Oct 1 | 2 days | Yen KristenSEE REMARKS | SSale | −3.11K | $49.43 | −$153.6K | −3.7%81.5K after | 2 lots |
| Jan 6, 2025 (view filing) | Jan 2-3 | 4 days | Anish BhatnagarCHIEF EXECUTIVE OFFICER | SSale | −21.1K | $45.78 | −$965.6K | −2.9%698.5K after | 3 lots |
| Jan 6, 2025 (view filing) | Jan 2-3 | 4 days | Hirano Patricia CSEE REMARKS | SSale | −3.03K | $45.78 | −$138.7K | −2.8%105.9K after | 3 lots |
| Jan 6, 2025 (view filing) | Jan 2-3 | 4 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −7.87K | $45.78 | −$360.5K | −6.6%111.3K after | 3 lots |
| Jan 6, 2025 (view filing) | Jan 2-3 | 4 days | Yen KristenSEE REMARKS | SSale | −4.86K | $45.78 | −$222.5K | −6.0%76.6K after | 3 lots |
| Mar 28, 2025 (view filing)7:03 PM ET | Mar 26-28 | 2 days | Vivo Opportunity, LLC and 1 other10% Owner | SSale | −1.83M | $67.87 | −$124.4M | −29.1%4.46M after | 3 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Anish BhatnagarCHIEF EXECUTIVE OFFICER | SSale | −699.1K | $67.62 | −$47.3M | −54.8%577.1K after | 12 lots |
| Mar 31, 2025 (view filing) | Mar 27-28 | 4 days | Hirano Patricia CSEE REMARKS | SSale | −156.3K | $68.51 | −$10.7M | −83.5%30.8K after | 16 lots10b5-1 |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Huang Michael F.Sr. VP of Clinical Development | SSale | −14.6K | $69.51 | −$1.01M | −28.4%36.8K after | 9 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −90.6K | $69.45 | −$6.29M | −46.3%105.2K after | 11 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Manning MeredithChief Commercial Officer | SSale | −45.2K | $67.28 | −$3.04M | −49.9%45.4K after | 9 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Yen KristenSEE REMARKS | SSale | −95.5K | $66.77 | −$6.38M | −77.2%28.1K after | 10 lots |
| Mar 31, 2025 (view filing) | Mar 28 | 3 days | Pauls MatthewDirector | SSale | −5.94K | $71.55 | −$424.8K | −47.7%6.50K after | |
| Apr 2, 2025 (view filing) | Apr 1 | 1 day | Hirano Patricia CSEE REMARKS | SSale | −3.78K | $70.11 | −$265.2K | −12.3%27.0K after | 10b5-1 |
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −266 | $84.25 | −$22.4K | −1.5%17.0K after | 10b5-1 |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −3.83K | $82.76 | −$317.0K | −22.5%13.2K after | 10b5-1 |
| Mar 31, 2026 (view filing) | Mar 27 | 4 days | Manning MeredithChief Commercial Officer | SSale | −7.52K | $30.44 | −$229.0K | −10.4%64.5K after | 3 lots |
| Mar 31, 2026 (view filing) | Mar 27 | 4 days | Huang Michael F.Sr. VP of Clinical Development | SSale | −6.58K | $30.44 | −$200.4K | −14.2%39.8K after | 3 lots |